SEQUENCE LISTING

<110> Fourie, Anne Coles, Fawn Karlsson, Lars			
<120> Aggrecanase-1 and -2 Peptide Substrates and Methods			
<130> ORT-1417			
<160> 60			
<170> PatentIn version 3.1			
<210> 1 <211> 1359 <212> DNA <213> Homo sapiens			
<220> <221> misc_feature <222> (1)(1359) <223> truncated Aggrecanase 1			
<400> 1 gaattcgcca tgtcccagac aggctcgcat cccgggaggg gcttggcagg gcgctggctg	60		
tggggagece aaccetgeet ectgeteece attgtgeege teteetgget ggtgtggetg	120		
cttctgctac tgctggcctc tctcctgccc tcagcccggc tggccagccc cctccccgg	180		
gaggaggaga tcgtgtttcc agagaagctc aacggcagcg tcctgcctgg ctcgggcacc	240		
cctgccaggc tgttgtgccg cttgcaggcc tttggggaga cgctgctact agagctggag	300		
caggactecg gtgtgeaggt egagggetg acagtgeagt acetgggeea ggegeetgag	360		
ctgctgggtg gagcagagcc tggcacctac ctgactggca ccatcaatgg agatccggag	420		
teggtggcat etetgcaetg ggatggggga geeetgttag gegtgttaea atateggggg	480		
getgaactee acetecagee eetggaggga ggeaceeeta actetgetgg gggaeetggg	540		
geteacatee tacgeeggaa gagteetgee ageggteaag gteecatgtg caacgteaag	600		
gctcctcttg gaagccccag ccccagaccc cgaagagcca agcgctttgc ttcactgagt	660		
agatttgtgg agacactggt ggtggcagat gacaagatgg ccgcattcca cggtgcgggg	720		
ctaaagcgct acctgctaac agtgatggca gcagcagcca aggccttcaa gcacccaagc	780		
atccgcaatc ctgtcagctt ggtggtgact cggctagtga tcctggggtc aggcgaggag	840		
gggccccaag tggggcccag tgctgcccag accetgcgca gettetgtge etggcagegg	900		
ggcctcaaca cccctgagga ctcggaccct gaccactttg acacagccat tctgtttacc	960		

cgtcaggacc tgtgtggagt ctccacttgc gacacgctgg gtatggctga tgtgggcacc 1020 gtctgtgacc cggctcggag ctgtgccatt gtggaggatg atgggctcca gtcagccttc 1080 actgetgete atgaactggg teatgtette aacatgetee atgacaacte caagecatge 1140 atcagtttga atgggccttt gagcacctct cgccatgtca tggcccctgt gatggctcat 1200 gtggateetg aggageeetg gteeecetge agtgeeeget teateaetga etteetggae 1260 aatggctatg ggcactgtct cttagacaaa ccagaggctc cattgcatct gcctgtgact 1320 ggggactaca aggacgacga tgacaagggg taggtcgac 1359 <210> <211> 1516 <212> DNA <213> Homo sapiens <220> <221> misc_feature (1)..(1516) truncated Aggrecanse-2 <400> gtcgacgcag cgcactatgc tgctcgggtg ggcgtccctg ctgctgtgcg cgttccgcct 60 gcccctggcc gcggtcggcc ccgccgcgac acctgcccag gataaagccg ggcagcctcc 120 gactgctgca gcagccgccc agccccgccg gcggcagggg gaggaggtgc aggagcgagc 180 cgagcctccc ggccacccgc acccctggc gcagcggcgc aggagcaagg ggctggtgca 240 gaacatcgac caactctact ccggcggcgg caaggtgggc tacctcgtct acgcgggcgg 300 ccgcaggttc ctcttggacc tggagcgaga tggttcggtg ggcattgctg gcttcgtgcc 360 cgcaggaggc gggacgagtg cgccctggcg ccaccggagc cactgcttct atcggggcac 420 agtggacggt agtccccgct ctctggctgt ctttgacctc tgtgggggtc tcgacggctt 480 ettegeggte aageaegege getacaeeet aaageeaetg etgegeggae eetgggegga 540 ggaagaaaag gggcgcgtgt acggggatgg gtccgcacgg atcctgcacg tctacacccg 600 cgagggette agettegagg ceetgeegee gegegeeage tgegaaacce cegegteeae 660 accggaggcc cacgagcatg ctccggcgca cagcaacccg agcggacgcg cagcactggc 720 etegeagete tiggaceagt cegetetete gecegetigg ggeteaggae egeagaegtig 780 gtggcggcgg cggccgct ccatctcccg ggcccgccag gtggagctgc ttctggtggc 840

tgacgcgtcc atggcgcggt tgtatggccg gggcctgcag cattacctgc tgaccctggc

900

```
ctccatcgcc aataggctgt acagccatgc tagcatcgag aaccacatcc gcctggccgt
                                                                      960
ggtgaaggtg gtggtgctag gcgacaagga caagagcctg gaagtgagca agaacgctgc
                                                                    1020
caccacactc aagaactttt gcaagtggca gcaccaacac aaccagctgg gagatgacca
                                                                     1080
tgaggagcac tacgatgcag ctatcctgtt tactcgggag gatttatgtg ggcatcattc
                                                                     1140
atgtgacacc ctgggaatgg cagacgttgg gaccatatgt tctccagagc gcagctgtgc
                                                                     1200
tgtgattgaa gacgatggcc tccacgcagc cttcactgtg gctcacgaaa tcggacattt
                                                                     1260
acttggcctc tcccatgacg attccaaatt ctgtgaagag acctttggtt ccacagaaga
                                                                     1320
taagegetta atgtetteea teettaeeag cattgatgea tetaageeet ggteeaaatg
                                                                     1380
cacttcagcc accatcacag aattcctgga tgatggccat ggtaactgtt tgctggacct
                                                                    1440
accacgaaag cagatcctgg gcggggacta caaggacgac gatgacaagg ggtagaagct
                                                                    1500
tgtcgagaag tactag
                                                                     1516
       3
<210>
       11
<211>
<212> PRT
<213> Artificial Sequence
<220>
<223> peptide substrate
<400> 3
Lys Glu Leu Ala Glu Leu Arg Glu Ser Thr Ser
<210>
       4
<211>
       11
<212>
       PRT
<213> Artificial Sequence
<220>
<223> Peptide substrate
<400> 4
Ala Asp Leu Ser Ser Phe Lys Ser Gln Glu Leu
<210>
       5
<211> 10
<212> PRT
```

la: b

M

ă!

ia k

<213> Artificial sequence

```
<220>
   <223> Peptide substrate
   <400> 5
   Glu Lys Ala Arg Val Leu Ala Glu Ala Ala
   <210> 6
   <211> 10
   <212> PRT
   <213> Artificial Sequence
   <220>
   <223> Peptide Substrate
   <400> 6
   Glu Lys Ala Arg Val Leu Ala Glu Ala Met
5
   <210> 7
   <211> 13
<212> PRT
   <213> Artificial Sequence
n
Ku
   <220>
   <223> Peptide substrate
¦∞ Þ
   <400> 7
i-b
Üİ
   Glu Arg Ala Glu Gln Gln Arg Leu Lys Ser Gln Asp Leu
Ħ
   <210> 8
   <211> 447
   <212> PRT
   <213> Homo sapiens
   <220>
   <221> MISC FEATURE
   <222> (1)..(447)
   <223> truncated Aggrecanase 1
   <400> 8
   Met Ser Gln Thr Gly Ser His Pro Gly Arg Gly Leu Ala Gly Arg Trp
   Leu Trp Gly Ala Gln Pro Cys Leu Leu Pro Ile Val Pro Leu Ser
               20
```

Trp Leu Val Trp Leu Leu Leu Leu Leu Leu Ala Ser Leu Leu Pro Ser 35 40 45

Ala Arg Leu Ala Ser Pro Leu Pro Arg Glu Glu Glu Ile Val Phe Pro 50 55 60

Glu Lys Leu Asn Gly Ser Val Leu Pro Gly Ser Gly Thr Pro Ala Arg 65 70 75 80

Leu Leu Cys Arg Leu Gln Ala Phe Gly Glu Thr Leu Leu Glu Leu 85 90 95

Glu Gln Asp Ser Gly Val Gln Val Glu Gly Leu Thr Val Gln Tyr Leu 100 105 110

Gly Gln Ala Pro Glu Leu Leu Gly Gly Ala Glu Pro Gly Thr Tyr Leu 115 120 125

Thr Gly Thr Ile Asn Gly Asp Pro Glu Ser Val Ala Ser Leu His Trp 130 135 140

Asp Gly Gly Ala Leu Leu Gly Val Leu Gln Tyr Arg Gly Ala Glu Leu 145 150 155 160

His Leu Gln Pro Leu Glu Gly Gly Thr Pro Asn Ser Ala Gly Gly Pro 165 170 175

Gly Ala His Ile Leu Arg Arg Lys Ser Pro Ala Ser Gly Gln Gly Pro 180 185 190

Met Cys Asn Val Lys Ala Pro Leu Gly Ser Pro Ser Pro Arg Pro Arg 195 200 205

Arg Ala Lys Arg Phe Ala Ser Leu Ser Arg Phe Val Glu Thr Leu Val 210 215 220

Val Ala Asp Asp Lys Met Ala Ala Phe His Gly Ala Gly Leu Lys Arg 225 230 235 240

Tyr Leu Leu Thr Val Met Ala Ala Ala Lys Ala Phe Lys His Pro 245 250 255

```
Ser Ile Arq Asn Pro Val Ser Leu Val Val Thr Arg Leu Val Ile Leu
            260
                                265
Gly Ser Gly Glu Gly Pro Gln Val Gly Pro Ser Ala Ala Gln Thr
        275
                            280
Leu Arg Ser Phe Cys Ala Trp Gln Arg Gly Leu Asn Thr Pro Glu Asp
Ser Asp Pro Asp His Phe Asp Thr Ala Ile Leu Phe Thr Arg Gln Asp
                    310
Leu Cys Gly Val Ser Thr Cys Asp Thr Leu Gly Met Ala Asp Val Gly
                                    330
                325
Thr Val Cys Asp Pro Ala Arg Ser Cys Ala Ile Val Glu Asp Asp Gly
            340
                                345
Leu Gln Ser Ala Phe Thr Ala Ala His Glu Leu Gly His Val Phe Asn
       355
                           360
                                                365
Met Leu His Asp Asn Ser Lys Pro Cys Ile Ser Leu Asn Gly Pro Leu
   370
                       375
Ser Thr Ser Arq His Val Met Ala Pro Val Met Ala His Val Asp Pro
                    390
Glu Glu Pro Trp Ser Pro Cys Ser Ala Arg Phe Ile Thr Asp Phe Leu
                405
                                    410
Asp Asn Gly Tyr Gly His Cys Leu Leu Asp Lys Pro Glu Ala Pro Leu
            420
                                425
His Leu Pro Val Thr Gly Asp Tyr Lys Asp Asp Asp Asp Lys Gly
        435
                            440
<210> 9
<211> 492
<212> PRT
<213> Homo sapiens
<220>
<221> MISC_FEATURE <222> (1)..(492)
```

. 200 H

IJ.

Mi

Œ,

<223> truncated Aggrecanse-2

<400> 9

Met Leu Leu Gly Trp Ala Ser Leu Leu Leu Cys Ala Phe Arg Leu Pro 1 5 10 15

Leu Ala Ala Val Gly Pro Ala Ala Thr Pro Ala Gln Asp Lys Ala Gly
20 25 30

Gln Pro Pro Thr Ala Ala Ala Ala Gln Pro Arg Arg Gln Gly
35 40 45

Glu Glu Val Gln Glu Arg Ala Glu Pro Pro Gly His Pro His Pro Leu 50 55 60

Ala Gln Arg Arg Arg Ser Lys Gly Leu Val Gln Asn Ile Asp Gln Leu 65 70 75 80

Tyr Ser Gly Gly Lys Val Gly Tyr Leu Val Tyr Ala Gly Gly Arg 85 90 95

Arg Phe Leu Leu Asp Leu Glu Arg Asp Gly Ser Val Gly Ile Ala Gly
100 105 110

Phe Val Pro Ala Gly Gly Gly Thr Ser Ala Pro Trp Arg His Arg Ser 115 120 125

His Cys Phe Tyr Arg Gly Thr Val Asp Gly Ser Pro Arg Ser Leu Ala 130 135 140

Val Phe Asp Leu Cys Gly Gly Leu Asp Gly Phe Phe Ala Val Lys His 145 150 155 160

Ala Arg Tyr Thr Leu Lys Pro Leu Leu Arg Gly Pro Trp Ala Glu Glu 165 170 175

Glu Lys Gly Arg Val Tyr Gly Asp Gly Ser Ala Arg Ile Leu His Val 180 185

Tyr Thr Arg Glu Gly Phe Ser Phe Glu Ala Leu Pro Pro Arg Ala Ser 195 200 205

Cys Glu Thr Pro Ala Ser Thr Pro Glu Ala His Glu His Ala Pro Ala

210	215	220

His Ser Asn Pro Ser Gly Arg Ala Ala Leu Ala Ser Gln Leu Leu Asp 225 230 235 240

Gln Ser Ala Leu Ser Pro Ala Gly Gly Ser Gly Pro Gln Thr Trp Trp 245 250 255

Arg Arg Arg Arg Ser Ile Ser Arg Ala Arg Gln Val Glu Leu Leu 260 265 270

Leu Val Ala Asp Ala Ser Met Ala Arg Leu Tyr Gly Arg Gly Leu Gln 275 280 285

His Tyr Leu Leu Thr Leu Ala Ser Ile Ala Asn Arg Leu Tyr Ser His 290 295 300

Hart than Mark

#:

n.

[]

Ala Ser Ile Glu Asn His Ile Arg Leu Ala Val Val Lys Val Val Val 305 310 315 320

Leu Gly Asp Lys Asp Lys Ser Leu Glu Val Ser Lys Asn Ala Ala Thr 325 330 335

Thr Leu Lys Asn Phe Cys Lys Trp Gln His Gln His Asn Gln Leu Gly 340 350

Asp Asp His Glu Glu His Tyr Asp Ala Ala Ile Leu Phe Thr Arg Glu 355 360 365

Asp Leu Cys Gly His His Ser Cys Asp Thr Leu Gly Met Ala Asp Val 370 375 380

Gly Thr Ile Cys Ser Pro Glu Arg Ser Cys Ala Val Ile Glu Asp Asp 385 390 395 400

Gly Leu His Ala Ala Phe Thr Val Ala His Glu Ile Gly His Leu Leu 405 410 415

Gly Leu Ser His Asp Asp Ser Lys Phe Cys Glu Glu Thr Phe Gly Ser 420 425 430

Thr Glu Asp Lys Arg Leu Met Ser Ser Ile Leu Thr Ser Ile Asp Ala 435 440 445

```
Ser Lys Pro Trp Ser Lys Cys Thr Ser Ala Thr Ile Thr Glu Phe Leu
    450
                        455
Asp Asp Gly His Gly Asn Cys Leu Leu Asp Leu Pro Arg Lys Gln Ile
465
                    470
Leu Gly Gly Asp Tyr Lys Asp Asp Asp Lys Gly
                485
<210> 10
<211> 13
<212> PRT
<213> Artificial sequence
<220>
<223> Peptide substrate
<400> 10
Glu His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg
<210> 11
<211> 4
<212> PRT
<213> Artificial sequence
<220>
<223> Peptide substrate
<400> 11
Glu Ala Glu Asn
<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> Peptide Substrate
<400> 12
Glu Gly Arg His Ile Asp Asn Glu Glu Asp Ile
               5
<210> 13
```

Mi

```
<211> 9
    <212> PRT
    <213> Artificial Sequence
   <220>
   <223> Peptide substrate
   <400> 13
   Glu Gly Asn Ala Phe Asn Asn Leu Asp
   <210> 14
   <211> 11
   <212> PRT
   <213> Artificial Sequence
   <220>
ju b
   <223> Peptide substrate
   <400> 14
Glu Tyr Thr Pro Asn Asn Glu Ile Asp Ser Phe
<210> 15
Sf
   <211> 8
   <212> PRT
   <213> Artificial sequence
jan is
171
   <220>
   <223> Peptide substrate
   <400> 15
   Glu Gln Leu Arg Met Lys Leu Pro
   <210> 16
   <211> 8
   <212> PRT
   <213> Artificial sequence
   <220>
   <223> Peptide substrate
   <400> 16
   Glu Arg Gly Phe Phe Tyr Thr Pro
   <210> 17
   <211> 8
```

```
<212> PRT
    <213> Artificial Sequence
    <220>
    <223> Peptide substrate
    <400> 17
    Glu Val Thr Glu Gly Pro Ile Pro
                   5
    <210> 18
    <211> 8
    <212> PRT
    <213> Artificial Sequence
    <220>
    <223> Peptide substrate
ļ, L
   <400> 18
   Glu Pro Leu Phe Tyr Glu Ala Pro
    <210> 19
   <211> 8
   <212> PRT
   <213> artificial sequence
ja 1
   <220>
61
   <223> peptide substrate
   <400> 19
   Glu Leu Pro Met Gly Ala Leu Pro
                  5
   <210> 20
   <211> 9
    <212> PRT
   <213> Artificial Sequence
   <220>
   <223> Peptide substrate
   <400> 20
   Glu Lys Pro Ala Ala Phe Phe Arg Leu
   <210> 21
   <211> 13
<212> PRT
```

is i

```
<213> Artificial sequence
    <220>
    <223> peptide substrate
    <400> 21
   Glu Leu Tyr Glu Asn Lys Pro Arg Arg Pro Tyr Ile Leu
    <210> 22
    <211> 10
    <212> PRT
    <213> Artificial sequence
   <220>
   <223> peptide substrate
   <400> 22
Sheet Hill Hill
   Glu Ser Glu Val Asn Leu Asp Ala Glu Phe
H
Mil.
   <210> 23
   <211> 9
   <212> PRT
   <213> Artificial Sequence
<220>
   <223> Peptide Substrate
124
<400> 23
   Glu Ser Gln Asn Tyr Pro Ile Val Gln
   <210> 24
   <211> 9
   <212> PRT
   <213> Artificial Sequence
   <220>
   <223> Peptide Substrate
   <400> 24
   Glu Lys Pro Ile Glu Phe Phe Arg Leu
   <210> 25
   <211> 9
   <212> PRT
   <213> Artificial sequence
```

```
<220>
    <223> Peptide substrate
    <400> 25
    Glu Lys Pro Ala Glu Phe Phe Ala Leu
                    5
    <210> 26
    <211> 9
    <212> PRT
    <213> Artificial sequence
    <220>
    <223> peptide substrate
    <400> 26
Han the Ann carry
    Glu Lys Pro Ala Lys Phe Phe Arg Leu
                    5
<210> 27
M.
    <211> 10
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
Į, i
    <400> 27
,
M
    Glu Ile Pro Phe His Leu Val Ile His Thr
                    5
    <210> 28
    <211> 11
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 28
   Glu Met Ala Pro Gly Ala Val His Leu Pro Gln
    <210> 29
    <211> 11
    <212> PRT
    <213> Artificial sequence
```

```
<220>
    <223> peptide substrate
    <400> 29
    Glu Pro Leu Ala Gln Ala Val Arg Ser Ser Ser
    <210> 30
    <211> 11
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 30
   Glu Pro Pro Val Ala Ala Ser Ser Leu Arg Asn
                   5
    <210> 31
    <211> 11
    <212> PRT
    <213> artificial sequence
    <220>
   <223> peptide substrate
   <400> 31
Glu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu
    <210> 32
    <211> 11
    <212> PRT
   <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 32
   Glu Ser Leu Pro Val Gln Asp Ser Ser Ser Val
    <210> 33
    <211> 11
    <212> PRT
    <213> artificial sequence
    <220>
```

100 1

[]

- i

1

MI

```
<223> peptide substrate
    <400> 33
    Glu Val His His Gln Lys Leu Val Phe Phe Ala
    <210> 34
    <211> 13
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 34
   Lys Arg Gly Val Val Asn Ala Ser Ser Arg Leu Ala Lys
<210> 35
    <211> 9
    <212> PRT
113
    <213> artificial sequence
    <220>
śi
    <223> peptide substrate
#1
in L
   <400> 35
į, i
   Lys Leu Val Leu Ala Ser Ser Ser Phe
ij1
M
   <210> 36
   <211> 13
    <212> PRT
   <213> artificial sequence
   <220>
   <223> peptide substrate
   <400> 36
   Lys Ser Asn Arg Leu Glu Ala Ser Ser Arg Ser Ser Pro
   <210> 37
   <211> 13
   <212> PRT
   <213> Artificial Sequence
   <220>
   <223> peptide substrate
```

```
<220>
    <221> MISC_FEATURE
    <222> (7)..(7)
    <223> "x" = aminobutyric acid
    <400> 37
    Glu Asp Glu Met Glu Glu Xaa Ala Ser His Leu Pro Tyr
    <210> 38
    <211> 13
    <212> PRT
    <213> Artificial sequence
    <220>
    <223> peptide substrate
# : .
<400> 38
Glu Ala Gly Pro Arg Gly Met Ala Gly Gln Phe Ser His
n,
<210> 39
    <211> 8
    <212> PRT
    <213> Artificial Sequence
ļ, L
    <220>
    <223> peptide substrate
   <400> 39
    Lys Arg Pro Leu Gly Leu Ala Arg
                   5
    <210> 40
    <211> 10
    <212> PRT
    <213> Artificial Sequence
    <220>
    <223> peptide substrate
    <400> 40
    Glu Gly Tyr Tyr Ser Arg Asp Met Leu Val
    <210> 41
    <211> 11
```

```
<212> PRT
                   <213> artificial sequence
                   <220>
                   <223> peptide substrate
                   <400> 41
                  Glu Gln Lys Leu Asp Lys Ser Phe Ser Met Ile
                   <210> 42
                   <211> 12
                   <212> PRT
                   <213> artificial sequence
                  <220>
                  <223> peptide substrate
and Ann. com ann. ann. oner and and B dans and dans been been dans dans dans dans and dans an
                 <400> 42
                Glu Pro Ser Ala Ala Gln Thr Ala Arg Gln His Pro
                  <210> 43
                 <211> 11
 #
                 <212> PRT
                <213> artificial sequence
 <220>
                <223> peptide substrate
 E.
                 <400> 43
                Glu Pro Gly Ala Gln Gly Leu Pro Gly Val Gly
                 <210> 44
                 <211> 8
                 <212> PRT
                 <213> artificial sequence
                 <220>
                 <223> peptide substrate
                 <400> 44
                Gly Leu Arg Thr Asn Ser Phe Ser
                 <210> 45
                 <211> 11
                 <212> PRT
```

```
<213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 45
   Arg Gly Val Val Asn Ala Ser Ser Arg Leu Ala
                   5
    <210> 46
    <211> 10
    <212> PRT
   <213> artificial sequence
   <220>
   <223> peptide substrate
   <400> 46
   Lys Pro Ile Leu Phe Phe Arg Leu Gly Lys
   <210> 47
   <211> 13
   <212> PRT
   <213> artificial sequence
   <220>
   <223> peptide substrate
(1)
   <400> 47
Glu Met His Thr Ala Ser Ser Leu Glu Lys Gln Ile Gly
   <210> 48
   <211> 11
   <212> PRT
   <213> artificial sequence
   <220>
   <223> peptide substrate
   <400> 48
   Glu Arg Phe Ala Gln Ala Gln Gln Gln Leu Pro
   <210> 49
   <211> 13
   <212> PRT
   <213> artificial sequence
```

THE STATE OF THE S

```
<220>
    <223> peptide substrate
    <400> 49
    Glu Lys Lys Glu Asn Ser Phe Glu Met Gln Gly Asp Gln
    <210> 50
    <211> 10
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 50
A H H H H
    Leu Ala Gln Ala Val Arg Ser Ser Ser Arg
<210> 51
Hand State
    <211> 9
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
la k
<400> 51
ij1
   Glu Arg Thr Ala Ala Val Phe Arg Pro
n.
    <210> 52
    <211> 8
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 52
   Glu Arg Val Arg Arg Ala Leu Pro
    <210> 53
    <211> 9
    <212> PRT
    <213> artificial sequence
```

```
<220>
    <223> peptide substrate
    <400> 53
    Glu Ser Phe Pro Arg Met Phe Ser Asp
    <210> 54
    <211> 11
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 54
   Glu Glu Tyr Leu Glu Ser Phe Leu Glu Arg Pro
          5
<210> 55
    <211> 12
    <212> PRT
    <213> artificial sequence
    <220>
   <223> peptide substrate
in i
   <400> 55
ļ, i
e i
   Glu Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
   <210> 56
    <211> 13
    <212> PRT
    <213> artificial sequence
    <220>
    <223> peptide substrate
    <400> 56
   Glu His Gly Asp Gln Met Ala Gln Lys Ser Gln Ser Thr
                   5
    <210> 57
    <211> 15
    <212> PRT
    <213> artificial sequence
    <220>
```

9)

```
<223> peptide substrate
   <400> 57
   Glu Arg Asn Ile Thr Glu Gly Glu Ala Arg Gly Ser Val Ile Leu
   <210> 58
   <211> 10
   <212> PRT
   <213> artificial sequence
   <220>
   <223> peptide substrate
   <400> 58
   Glu Ala Gly Gln Arg Leu Ala Thr Ala Met
, m
<210> 59
   <211> 12
   <212> PRT
n,
   <213> artificial sequence
Ľ.
   <220>
   <223> peptide substrate
<400> 59
in h
   Glu Val Gly Leu Met Gly Lys Arg Ala Leu Asn Ser
<210> 60
   <211> 12
   <212> PRT
   <213> artificial sequence
   <220>
   <223>
          peptide substrate
   <400> 60
   Glu Lys Glu Asp Gly Glu Ala Arg Ala Ser Thr Ser
```